NCT05245669
Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, Tolerability, and Immunogenicity of Biosimilar Denosumab With Prolia® in Healthy Adult Male Volunteers
Phase: Phase 1
Role: Collaborator
Start: Feb 7, 2022
Completion: May 31, 2024